spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  nephrotic syndrome 

 HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2015
U.S. Food and Drug Administration Approves Cholbam for the Treatment of Rare Bile Acid Synthesis Disorders and Grants Rare Pediatric Disease Priority Review Voucher
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2014
Retrophin Names Stephen Aselage President and Chief Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Nov 2010
New Data on H.P. Acthar(R) Gel in the Treatment of Nephrotic Syndrome Presented at the American Society of Nephrology 43rd Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 22 Nov 2010
Interim Results From Independent Study of H.P. Acthar(R) Gel in Patients With Advanced Diabetic Nephropathy Presented at American Society of Nephrology 43rd Annual Meeting
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 3 Nov 2010
Questcor Pharmaceuticals Launches Acthar for the Treatment of Infantile Spasms
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2010
FDA Approves H.P. Acthar(R) Gel for the Treatment of Infantile Spasms
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 24 Dec 2009
FDA Accepts for Review Questcor's Filing of Its Supplemental New Drug Application for H.P. Acthar(R) Gel for Treatment of Infantile Spasms
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2009
Louis Silverman Appointed to Questcor Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Dec 2007
Genentech Provides Update from Avastin FDA Advisory Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2006
Ranbaxy Receives Approval to Commercialize Furosemide Tablets in the U.S.
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2006
Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2006
Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 13

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 13 additional stories matching:
nephrotic syndrome
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.